Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

Lymphoma
24:13

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Low-Grade Lymphoproliferative Disorders: Does Bendamustine Improve PFS and Can We Combine It With Obinutuzumab in MCL? Is Rituximab a Good Option for MCL/FL? Is 1L Ibrutinib Alone Enough? How Can We Use Venetoclax?

FEATURING Argiris S. Symeonidis
  • 14 views
  • January 19, 2021
29:22

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Indolent Lymphomas: How to Define High TMB Patients? Does Reduced-Dose RT Improve OS/PFS in NHL? Should We Use Rituximab for Untreated FL? Does High-Dose Chemo & ASCT Prolong Survival in Relapsed Disease?

FEATURING Carmino De Souza
  • 115 views
  • January 19, 2021
  • 1
20:43

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Early Relapsed Follicular Lymphoma: Is POD24 a Good OS Predictor? What Is the Best Management Approach for High-Risk Disease With POD?

FEATURING Ozan Salim
  • 9 views
  • January 18, 2021
20:32

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Malignancy Associated Hemophagocytic Lymphohistiocytosis: Diagnosis & Evaluation, Role of sCD25, Specific Therapeutic Approaches, New Diagnostic Markers

FEATURING Sevgi Kalayoglu Besisik
  • 38 views
  • January 18, 2021
23:45

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

ASCT in MCL: Are There Patients Who Don't Benefit From ASCT? Does Pre-Transplant MRD Predict Survival Outcomes? Can Novel Agents Eliminate the Need for ASCT?

FEATURING Elif Birtas Atesoglu
  • 10 views
  • January 18, 2021
24:18

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Waldenstrom's Macroglobulinemia Updates: What Chemoimmunotherapy Combo Is the Best? Should We Use Ibrutinib Alone or Combined With IO? Is Venetoclax Efficient For Previously Treated Disease?

FEATURING Ahmad Ibrahim
  • 213 views
  • January 15, 2021
12:17

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

NGS in DLBCL: Gene Mutations and Results, Statistic Analysis With SPSS 17.0, Distribution, Treatment Response

FEATURING Azime Ozcalimli
  • 109 views
  • January 12, 2021
23:43

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Prospects for IO for Malignant Pleural Effusions: Secretome, Dampened Effector Response, CAR-T Experience

FEATURING Vera Donnenberg, Albert Donnenberg
  • 40 views
  • January 12, 2021
22:39

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Lymphoblastic Lymphoma: How Effective Are ALL-Regimen Therapy and CHOP-Like Chemo? What Is the Role of AutoSCT and RT?

FEATURING Alina Antipova
  • 145 views
  • January 12, 2021
15:40

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

IO for R/R cHL: Optimal Treatment Regimen, Therapy Duration & Discontinuation, Prognostic Factors, Treatment Strategy in Case of Resistance

FEATURING Kirill Lepik
  • 11 views
  • January 12, 2021
23:43

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

DLBCL Updates: Should High-Risk Patients Be Treated With RCHOP? Does Dose Intensification Improve Outcomes? Is PET-Guided Therapy a SoC?

FEATURING Christian Gisselbrecht
  • 456 views
  • January 11, 2021
  • 1